TY - JOUR
T1 - Successful Healthcare Provider Strategies to Overcome Psychological Insulin Resistance in Japanese Patients with Type 2 Diabetes
AU - Okazaki, Kentaro
AU - Shingaki, Tomotaka
AU - Cai, Zhihong
AU - Perez-Nieves, Magaly
AU - Fisher, Lawrence
N1 - Funding Information:
We thank the participants and the study personnel who participated in this study. Project management support was provided by Aki Yoshikawa from Eli Lilly Japan K.K.
Funding Information:
This study was sponsored by Eli Lilly and Company (Indianapolis, IN, USA) and Boehringer Ingelheim (Ingelheim, Germany). Eli Lilly Japan K.K. (Kobe, Japan) and Nippon Boehringer Ingelheim Co., Ltd. (Tokyo, Japan) funded the Rapid Service Fee. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.
Funding Information:
We thank the participants and the study personnel who participated in this study. Project management support was provided by Aki Yoshikawa from Eli Lilly Japan K.K. This study was sponsored by Eli Lilly and Company (Indianapolis, IN, USA) and Boehringer Ingelheim (Ingelheim, Germany). Eli Lilly Japan K.K. (Kobe, Japan) and Nippon Boehringer Ingelheim Co., Ltd. (Tokyo, Japan) funded the Rapid Service Fee. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. Medical writing support was provided by Lisa Cossens and editorial support was provided by Angela Lorio, both of Syneos Health. Medical writing and editorial assistance was funded by Eli Lilly and Company. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Kentaro Okazaki reports an advisory role with Eli Lilly and Company, Japan K.K. Tomotaka Shingaki is an employee and stockholder at Eli Lilly Japan K.K. Zhihong Cai is an employee and stockholder at Eli Lilly Japan K.K. Magaly Perez-Nieves is an employee and stockholder at Eli Lilly and Company. Lawrence Fisher serves as an advisor for Eli Lilly and Company and has received travel grants from Eli Lilly and Company. The study protocol was approved by the Western Institutional Review Board (IRB), Puyallup, Washington, USA, as well as the Nagoya University IRB, Nagoya, Japan. All procedures performed in this study involving human participants were in accordance with the ethical standards of the Western IRB, Puyallup, Washington, USA, and Nagoya University IRB, Nagoya, Japan, and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study. Participants were compensated for their time. The datasets of the current study are not publicly available. Eli Lilly and company provides access to individual patient data from studies on approved medicines and indications as defined by the sponsor-specific information at http://clinicalstudydatarequest.com. Researchers require an approved research proposal submitted through http://clinicalstudydatarequest.com. Access to data will be provided in a secure data sharing environment after signing a data sharing agreement. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Publisher Copyright:
© 2019, The Author(s).
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Introduction: EMOTION was a multinational, noninterventional study surveying current insulin-using adults with type 2 diabetes mellitus (T2D) who were initially reluctant to begin insulin treatment. In this Japanese population subanalysis of EMOTION, we identify the frequency and level of helpfulness of healthcare provider (HCP) actions, and we analyze life events (‘actions/events’) that assist T2D patients with psychological insulin resistance in the decision to initiate insulin. Methods: Participants were selected from Survey Sampling International and their local partners’ market research panels in Japan. Quantitative surveys were administered between December 2016 and August 2017 to patients who met the study criteria. Participants were asked whether 45 actions/events occurred, and to rate the level of helpfulness of the actions/events in contributing to their decision to initiate insulin. Results: Among the 594 eligible participating adults in the EMOTION study, 99 were from Japan. Despite initial reluctance to begin insulin treatment, 80.8% of the Japanese participants immediately commenced insulin. Practical demonstrations by HCPs on how to use insulin were rated by participants as most helpful. Examples of such practical demonstrations, reported as helping moderately or a lot, were ‘HCP walked patient through the process of exactly how to take insulin’ (82.8%), ‘HCP showed an insulin pen’ (79.7%), and ‘HCP helped patient to see how simple it was to inject insulin’ (79.1%). Conclusion: This study identifies actions that HCPs can use to assist Japanese patients in deciding whether to initiate insulin. These findings may aid the development of clinical interventions addressing reluctance to begin insulin treatment among Japanese patients with T2D. Funding: Eli Lilly and Company and Boehringer Ingelheim. Plain Language Summary: Plain language summary available for this article.
AB - Introduction: EMOTION was a multinational, noninterventional study surveying current insulin-using adults with type 2 diabetes mellitus (T2D) who were initially reluctant to begin insulin treatment. In this Japanese population subanalysis of EMOTION, we identify the frequency and level of helpfulness of healthcare provider (HCP) actions, and we analyze life events (‘actions/events’) that assist T2D patients with psychological insulin resistance in the decision to initiate insulin. Methods: Participants were selected from Survey Sampling International and their local partners’ market research panels in Japan. Quantitative surveys were administered between December 2016 and August 2017 to patients who met the study criteria. Participants were asked whether 45 actions/events occurred, and to rate the level of helpfulness of the actions/events in contributing to their decision to initiate insulin. Results: Among the 594 eligible participating adults in the EMOTION study, 99 were from Japan. Despite initial reluctance to begin insulin treatment, 80.8% of the Japanese participants immediately commenced insulin. Practical demonstrations by HCPs on how to use insulin were rated by participants as most helpful. Examples of such practical demonstrations, reported as helping moderately or a lot, were ‘HCP walked patient through the process of exactly how to take insulin’ (82.8%), ‘HCP showed an insulin pen’ (79.7%), and ‘HCP helped patient to see how simple it was to inject insulin’ (79.1%). Conclusion: This study identifies actions that HCPs can use to assist Japanese patients in deciding whether to initiate insulin. These findings may aid the development of clinical interventions addressing reluctance to begin insulin treatment among Japanese patients with T2D. Funding: Eli Lilly and Company and Boehringer Ingelheim. Plain Language Summary: Plain language summary available for this article.
UR - http://www.scopus.com/inward/record.url?scp=85068846702&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068846702&partnerID=8YFLogxK
U2 - 10.1007/s13300-019-0664-9
DO - 10.1007/s13300-019-0664-9
M3 - Article
AN - SCOPUS:85068846702
SN - 1869-6953
VL - 10
SP - 1823
EP - 1834
JO - Diabetes Therapy
JF - Diabetes Therapy
IS - 5
ER -